ArticleCureus2025
Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist Therapy: A Rare and Life-Threatening Complication.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary apoplexy is a rare but potentially life-threatening endocrine emergency characterized by acute hemorrhage or infarction of the pituitary gland. While often associated with pre-existing adenomas, it may also occur in previously normal glands. Risk factors include surgery, pregnancy, and medications such as gonadotropin-releasing hormone (GnRH) agonists, which are rarely implicated in pituitary apoplexy. We present the case of a 59-year-old male with a history of type 2 diabetes mellitus, hypertension, hyperlipidemia, and prostate cancer who developed intractable headache, nausea, vomiting, photophobia, and blurred vision shortly after receiving a leuprolide, GnRH agonist injection, for the treatment of prostate cancer. Brain imaging revealed a sellar and suprasellar pituitary tumor with hemorrhage. He was treated with intravenous fluids and steroids. The patient underwent emergent transsphenoidal hypophysectomy surgery, and pathology confirmed a gonadotroph adenoma with necrosis. The patient was discharged in stable condition. Pituitary apoplexy following GnRH agonist therapy is exceedingly rare, with fewer than 30 cases reported in the public domain. Proposed mechanisms include sudden cell shrinkage and metabolic hyperactivity within the pituitary gland. This case underscores the importance of recognizing the clinical presentation of pituitary apoplexy, as timely diagnosis and treatment are crucial to preventing severe neurological and endocrine sequelae. Clinicians should maintain a high index of suspicion for pituitary apoplexy in patients presenting with acute neurological or endocrine symptoms following GnRH agonist therapy. Increased awareness and vigilance in at-risk populations are essential, as routine pre-screening for pituitary adenomas is not currently standard practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.